Entry | Author | Date | Location | |
---|---|---|---|---|
GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca | Ben Fidler | 12/03/18 | Boston | |
Heron Gains FDA Support For Nausea Drug After A Year Under Review | David Holley | 08/10/16 | San Francisco | |
East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More | Ben Fidler | 09/04/15 | Boston | |
Page 1 of 1 | ||||